Jan 23 2025 11 mins
In this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more.
Read the full coverage here:
Combination extends survival vs. standard first-line therapy for advanced lung cancer
Integrated care ‘best treatment option’ for smoking cessation during lung cancer screening
FDA proposes cap on nicotine levels in cigarettes
Global lifetime risk for lung cancer in 2022 differs by human development index, sex
FDA grants priority review to oral non-small cell lung cancer drug
References:
Cinciripini P, et al. JAMA Intern Med. 2024;doi:10.1001/jamainternmed.2024.7288.
Li M, et al. Chin Med J (Engl). 2024;doi:10.1097/CM9.0000000000003368.